Pharmacokinetics: Routes of Drug Administration

Introduction

Pharmacokinetics (PK) encompasses the quantitative study of drug absorption, distribution, metabolism, and excretion (ADME). A fundamental component of PK is the route of drug administration, which determines the initial site of action, the rate and extent of systemic exposure, and ultimately the therapeutic and adverse effects of a medicinal product. Historically, early pharmacologists such as Galen and later William Withering laid the groundwork for systematic observations of drug absorption, yet it was the advent of quantitative analysis in the 20th century that transformed these qualitative insights into precise mathematical models.

The importance of understanding routes of administration is underscored by the fact that a single drug can exhibit markedly different pharmacokinetic profiles depending on whether it is delivered orally, intravenously, intramuscularly, or via transdermal or pulmonary routes. Clinical decision-making, therapeutic drug monitoring, and formulation science all rely on accurate predictions of how a drug will behave once introduced into the body through a specific pathway.

Learning objectives for this chapter include:

• Defining the principal routes of drug administration and their pharmacokinetic implications.
• Exploring the mechanisms governing absorption and first‑pass effects for each route.
• Applying mathematical relationships to estimate key PK parameters such as C_max, t_1/2, and AUC.
• Identifying clinical scenarios where route selection influences therapeutic outcomes.
• Integrating PK principles into drug development and patient management strategies.

Fundamental Principles

Core Concepts and Definitions

Routes of drug administration are categorised based on the anatomical pathway through which a drug enters the body. The most frequently studied routes include intravenous (IV), oral (PO), intramuscular (IM), subcutaneous (SC), inhalation, transdermal, rectal, and intranasal. Each route is characterised by its own pharmacokinetic parameters: the rate of absorption (k_a), the bioavailability (F), and the extent of first‑pass extraction. Bioavailability represents the fraction of an administered dose that reaches systemic circulation unchanged and is expressed as a percentage of the IV dose.

Theoretical Foundations

Mathematical modelling of drug disposition often employs compartmental analysis. A one‑compartment model for IV administration yields the exponential decay equation: C(t) = C₀ × e⁻ᵏᵗ, where C_t is the plasma concentration at time t, C₀ is the initial concentration, and k is the elimination rate constant. For extravascular routes, absorption is modelled by an additional term: C(t) = (F × Dose × k_a)/(V_d(k_a−k)) × (e⁻ᵏt − e⁻ᵏ_at), where V_d is the apparent volume of distribution. These equations allow calculation of C_max (peak concentration), t_max (time to peak), and t_1/2 (elimination half‑life).

Key Terminology

• Absorption – the process by which a drug moves from the site of administration into the bloodstream.
• First‑pass effect – hepatic or gastrointestinal extraction of a drug before it reaches systemic circulation.
• Bioavailability (F) – the fraction of an administered dose that is available systemically.
• Plasma protein binding – the proportion of drug bound to albumin or alpha‑1‑acid glycoprotein, influencing distribution and clearance.
• Clearance (Cl) – the volume of plasma from which the drug is completely removed per unit time, expressed as Cl = Dose/AUC.

Detailed Explanation

Oral Route

Oral administration is the most common route owing to its convenience. Oral absorption occurs primarily in the small intestine, where the drug must dissolve in luminal fluid, traverse the epithelial barrier, and evade gastrointestinal metabolism. The rate of absorption (k_a) is influenced by factors such as gastric pH, intestinal motility, and the presence of food. The first‑pass effect is most pronounced for drugs with extensive hepatic metabolism, leading to reduced bioavailability (often < 30 %). Mathematical models often incorporate a lag time (t_lag) to account for delayed gastric emptying.

Intravenous Route

IV administration delivers the drug directly into systemic circulation, bypassing absorption barriers and first‑pass metabolism. Bioavailability is therefore 100 %. The drug’s distribution is governed by plasma protein binding and the tissue perfusion rate. For hydrophilic drugs, distribution is limited to the vascular and interstitial spaces; for lipophilic drugs, redistribution into adipose tissue may occur, prolonging the terminal half‑life. The IV route is ideal for rapid onset of action and for drugs with low oral bioavailability.

Intramuscular and Subcutaneous Routes

IM and SC injections deposit the drug into highly vascularised muscle or subcutaneous tissue, respectively. Absorption depends on local blood flow, lipophilicity, and the presence of a depot formulation (e.g., lipid‑based). IM absorption is generally faster than SC due to greater perfusion, but both routes can achieve extended release when formulated as microspheres or hydrogels. First‑pass extraction is negligible, yet systemic bioavailability may be slightly reduced compared to IV due to the time required for drug dissolution and diffusion.

Inhalation Route

Inhaled drugs reach the systemic circulation via the alveolar-capillary barrier. The rapid onset is attributable to the extensive surface area of the lungs and the thinness of the alveolar epithelium. Bioavailability is highly variable, ranging from 20 % to > 90 % depending on particle size, formulation, and breathing technique. The pulmonary route is advantageous for local pulmonary action (e.g., bronchodilators) and for systemic delivery of peptide drugs that are unstable in the gastrointestinal tract.

Transdermal Route

Transdermal patches deliver drugs across the stratum corneum into systemic circulation, circumventing first‑pass metabolism. Skin permeability is a major determinant of absorption; factors such as drug lipophilicity, molecular weight (< 500 Da), and the presence of permeation enhancers modulate flux. The transdermal route provides a controlled, steady release, which is particularly useful for drugs with narrow therapeutic windows. Bioavailability may be reduced by skin metabolism and variability in skin thickness.

Rectal Route

Rectal administration offers an alternative to oral delivery, especially for patients with impaired gastrointestinal absorption. Drugs absorbed via the rectal mucosa can bypass hepatic first‑pass extraction if they enter the systemic circulation through the upper rectal veins. However, drugs absorbed through the lower rectal veins are still subjected to first‑pass metabolism. The rectal route is commonly used for antiemetics and for drugs requiring rapid onset when oral administration is contraindicated.

Intranasal Route

Intranasal delivery exploits the rich vascular network of the nasal cavity, providing a rapid onset for both systemic and central nervous system effects. The nasal mucosa’s permeability is influenced by humidity, mucociliary clearance, and the presence of enzymatic activity. Formulations often incorporate mucoadhesive polymers to prolong contact time and improve absorption. The intranasal route is particularly valuable for peptide drugs and for agents requiring rapid symptom relief (e.g., intranasal fentanyl for breakthrough pain).

Factors Affecting Absorption Across Routes

Intrinsic factors such as drug physicochemical properties (solubility, lipophilicity, ionization) and extrinsic factors such as formulation excipients, delivery device, and patient-specific variables (age, comorbidities, concomitant medications) collectively determine the absorption profile. For instance, the presence of P‑glycoprotein efflux pumps in the intestinal epithelium can limit oral absorption of certain substrates, while co‑administration of inhibitors can enhance bioavailability. Similarly, hepatic blood flow and enzyme induction or inhibition modulate the magnitude of first‑pass extraction across all extravascular routes.

Clinical Significance

Influence on Therapeutic Outcomes

Route selection directly affects the onset of action, peak concentration, and duration of effect. For critically ill patients requiring immediate haemodynamic support, IV administration guarantees rapid attainment of therapeutic levels. Conversely, chronic pain management might benefit from transdermal patches that deliver a consistent plasma concentration over days, thereby minimizing peaks and troughs that could precipitate side effects or withdrawal phenomena.

Practical Applications in Drug Development

Pharmaceutical developers routinely evaluate multiple routes during formulation development to optimise pharmacokinetic profiles. For example, the development of extended‑release oral tablets often employs matrix systems that modulate k_a and achieve a desired C_max while maintaining a steady AUC. Similarly, lipid‑based nanoemulsions have been engineered to enhance oral bioavailability of poorly soluble agents, thereby reducing the need for IV formulations.

Clinical Examples

1. Warfarin – an oral anticoagulant with narrow therapeutic index. Its bioavailability is reduced by food and hepatic metabolism; thus, patient education on dietary consistency is essential. Monitoring of INR mitigates the risk of sub‑therapeutic or supra‑therapeutic levels.

2. Insulin – traditionally administered subcutaneously. Rapid‑acting analogues with shorter k_a achieve faster onset, whereas long‑acting formulations sustain a near‑constant release, reducing hypoglycaemic episodes.

3. Albuterol – a bronchodilator delivered via inhalation. The pulmonary route enables rapid relief of bronchospasm, with minimal systemic exposure; however, improper inhalation technique can compromise efficacy.

Clinical Applications/Examples

Case Scenario 1: Acute Pain Management in a Post‑Operative Patient

A 55‑year‑old male undergoes abdominal surgery and requires analgesia. Intravenous morphine provides rapid onset but carries the risk of respiratory depression. An alternative is the intranasal fentanyl formulation, which delivers sufficient systemic exposure within minutes while reducing respiratory compromise. The clinician must consider the patient’s nasal mucosa status and potential for mucociliary clearance when selecting this route.

Case Scenario 2: Chronic Hypertension in an Elderly Patient with Renal Impairment

The patient is prescribed an oral angiotensin‑converting enzyme inhibitor. Renal impairment may affect drug clearance, leading to accumulation. Switching to a transdermal formulation of a vasodilator can bypass hepatic metabolism and reduce variability in plasma concentration, thereby improving blood pressure control.

Problem‑Solving Approach

1. Identify therapeutic goal – rapid onset, sustained release, or targeted delivery.
2. Assess drug properties – solubility, lipophilicity, half‑life, and metabolic pathways.
3. Evaluate patient factors – age, organ function, comorbidities, and adherence potential.
4. Select route – balancing pharmacokinetic benefits with practical considerations (device availability, patient preference).
5. Monitor therapeutic response – through clinical assessment and, where appropriate, therapeutic drug monitoring.

Summary/Key Points

• Routes of drug administration determine the rate and extent of absorption, influencing bioavailability and the onset of action.
• Mathematical models such as C(t) = C₀ × e⁻ᵏt and C(t) = (F × Dose × k_a)/(V_d(k_a−k)) × (e⁻ᵏt − e⁻ᵏ_at) provide a framework for estimating PK parameters.
• First‑pass metabolism is a critical determinant of oral bioavailability and can be mitigated by alternative routes such as IV, transdermal, or pulmonary.
• Clinical decisions regarding route selection should incorporate drug physicochemical properties, patient-specific factors, and therapeutic objectives.
• Therapeutic drug monitoring and patient education are essential to optimise outcomes across all routes of administration.

References

1. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Philadelphia: Wolters Kluwer; 2011.
2. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 7th ed. New York: McGraw-Hill Education; 2016.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.